We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+29.13%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$244M
AUM Growth
+$22M
Cap. Flow
-$10.5M
Cap. Flow %
-4.28%
Top 10 Hldgs %
43.92%
Holding
93
New
19
Increased
15
Reduced
7
Closed
46

Top Buys

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$10.8M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.94M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$9.37M
4
BLUE
bluebird bio
BLUE
+$9.25M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.83M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.4M
2
AGN
Allergan plc
AGN
+$10.2M
3
GILD icon
Gilead Sciences
GILD
+$6.87M
4
CELG
Celgene Corp
CELG
+$6.49M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$5.71M

Sector Composition

Rank Sector Weight
1 Healthcare 89.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
51
Atara Biotherapeutics
ATRA
$75.6M
– –
-4,000
Closed -$3.14M
AVDL
52
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-350,000
Closed -$5.71M
BCRX icon
53
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-225,000
Closed -$2.56M
BMY icon
54
CALL
Bristol-Myers Squibb
BMY
$124B
– –
-100,000
Closed -$5.92M
CLLS
55
Cellectis
CLLS
$265M
– –
-75,000
Closed -$1.98M
CYH icon
56
Community Health Systems
CYH
$465M
– –
-145,200
Closed -$5.13M
EW icon
57
Edwards Lifesciences
EW
$49.4B
– –
-240,000
Closed -$5.69M
FATE icon
58
Fate Therapeutics
FATE
$324M
– –
-89,231
Closed -$476K
GILD icon
59
Gilead Sciences
GILD
$167B
– –
-70,000
Closed -$6.87M
HCA icon
60
HCA Healthcare
HCA
$82.3B
– –
-50,000
Closed -$3.87M
HRTX icon
61
CALL
Heron Therapeutics
HRTX
$89.1M
– –
-100,000
Closed -$2.44M
IOVA icon
62
Iovance Biotherapeutics
IOVA
$2.23B
– –
-300,000
Closed -$1.73M
ISRG icon
63
Intuitive Surgical
ISRG
$122B
– –
-63,000
Closed -$3.22M
LRMR icon
64
Larimar Therapeutics
LRMR
$384M
– –
-5,417
Closed -$2.08M
NBIX icon
65
Neurocrine Biosciences
NBIX
$17.2B
– –
-55,000
Closed -$2.19M
PBYI icon
66
Puma Biotechnology
PBYI
$434M
– –
-6,500
Closed -$490K
PTCT icon
67
CALL
PTC Therapeutics
PTCT
$6.52B
– –
-75,000
Closed -$2M
QURE icon
68
uniQure
QURE
$2.77B
– –
-150,000
Closed -$3.07M
TXMD icon
69
CALL
TherapeuticsMD
TXMD
$23.8M
– –
-10,000
Closed -$2.93M
VIRX
70
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,395
Closed -$237K
BIOL
71
DELISTED
Biolase, Inc.
BIOL
– –
-24
Closed -$270K
CBAY
72
DELISTED
Cymabay Therapeutics
CBAY
– –
-400,000
Closed -$776K
BLCM
73
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-20,000
Closed -$2.91M
EPZM
74
DELISTED
Epizyme, Inc
EPZM
– –
-150,000
Closed -$1.93M
ZSAN
75
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-143
Closed -$396K
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Ghost Tree Capital held 93 positions worth $244M, up 9.9% from $222M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital withdrew a net $10.5M in Q4 2015, closing 46 positions and reducing 7 holdings. Its most notable exit was Allergan plc, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Wright Medical Group Inc worth $12.1M.

  • Ghost Tree Capital's largest Q4 2015 buy was Wright Medical Group Inc: 500,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Portola Pharmaceuticals, Inc. in Q4 2015, an estimated $9.94M increase.
  • Ghost Tree Capital's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $13.4M.
  • Ghost Tree Capital fully exited Allergan plc in Q4 2015, selling an estimated $10.2M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $244M portfolio in Q4 2015.
  • Ghost Tree Capital opened 19 new positions and closed 46 in Q4 2015.
  • Ghost Tree Capital's portfolio value rose 9.9% quarter-over-quarter to $244M.

Based on Ghost Tree Capital's 13F filing for Q4 2015, filed 16 Feb 2016.